Thera-SAbDab

LUMRETUZUMAB

>   Structural Summary
TherapeuticLumretuzumab
TargetERBB3
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFRSSYISWVRQAPGQGLEWMGWIYAGTGSPSYNQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARHRDYYSNSLTYWGQGTLVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCKSSQSVLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQSDYSYPYTFGQGTKLEIK
100% seqID Fv Structure4leo [Fvs: AB]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental TechnologyGlycoMAb Technology
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedRoche
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer
Conditions DiscontinuedBreast cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]